![]() | |
Names | |
---|---|
IUPAC name
N1-{2-Methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethen-1-yl]phenyl}-L-serinamide
| |
Systematic IUPAC name
(2S)-2-Amino-3-hydroxy-N-{2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethen-1-yl]phenyl}propanamide | |
Other names
AVE-8062; AVE-8062A; AC7700; CS-39-L-Ser.HCl
| |
Identifiers | |
3D model (
JSmol)
|
|
ChemSpider | |
PubChem
CID
|
|
UNII | |
CompTox Dashboard (
EPA)
|
|
| |
| |
Properties | |
C21H26N2O6 | |
Molar mass | 402.447 g·mol−1 |
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
Ombrabulin was an experimental drug candidate discovered by Ajinomoto and further developed by Sanofi-Aventis. [1] Ombrabulin is a combretastatin A-4 derivative that exerts its antitumor effect by disrupting the formation of blood vessels needed for tumor growth. [2] [3]
It was granted orphan drug status by the European Medicines Agency in April 2011. [4]
In January 2013, Sanofi said it discontinued development of ombrabulin after disappointing results from phase III clinical trials. [5]
![]() | |
Names | |
---|---|
IUPAC name
N1-{2-Methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethen-1-yl]phenyl}-L-serinamide
| |
Systematic IUPAC name
(2S)-2-Amino-3-hydroxy-N-{2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethen-1-yl]phenyl}propanamide | |
Other names
AVE-8062; AVE-8062A; AC7700; CS-39-L-Ser.HCl
| |
Identifiers | |
3D model (
JSmol)
|
|
ChemSpider | |
PubChem
CID
|
|
UNII | |
CompTox Dashboard (
EPA)
|
|
| |
| |
Properties | |
C21H26N2O6 | |
Molar mass | 402.447 g·mol−1 |
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
Ombrabulin was an experimental drug candidate discovered by Ajinomoto and further developed by Sanofi-Aventis. [1] Ombrabulin is a combretastatin A-4 derivative that exerts its antitumor effect by disrupting the formation of blood vessels needed for tumor growth. [2] [3]
It was granted orphan drug status by the European Medicines Agency in April 2011. [4]
In January 2013, Sanofi said it discontinued development of ombrabulin after disappointing results from phase III clinical trials. [5]